Bridgebio Pharma Inc. (bbio 2.25 02/01/29)
13F holders, Q1 2024 (March 31)4holders
$0.82avg. 13F price*
At the end of Q1 2024, 4 institutions reported holding Bridgebio Pharma Inc. (bbio 2.25 02/01/29) in their 13F filings. The largest holders were Lord, Abbett & Co. LLC ($8.2M), New York State Common Retirement Fund ($4.8M) and BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($2.0M).
- Company
- Bridgebio Pharma Inc. (bbio 2.25 02/01/29)
- CUSIP
- 10806XAD4
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $127K |
| Exits | 2 | $4.5M |
Ownership 4 holders
| Lord, Abbett & Co. LLC | 0.03% | Add +19.0% | 9,948,000 | $8.2M |
| New York State Common Retirement Fund | 0.01% | Add +8.2% | 5,872,000 | $4.8M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.01% | No change | 2,500,000 | $2.0M |
| Sei Investments Co. | 0.00% | New | 156,000 | $127K |
"% of holder's portfolio" is BRIDGEBIO PHARMA INC (BBIO 2.25 02/01/29)'s weight in each manager's 13F, not the share of Bridgebio Pharma Inc. (bbio 2.25 02/01/29) the manager owns.